Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of AromasinĀ® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of SutentĀ® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell lung cancer (NSCLC).
More...